Lithera Reports Positive Clinical Study Results From a Second Phase IIa Trial for LIPO-102, a Novel Treatment for …
SAN DIEGO — Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction.
Read more on GlobeNewswire via Yahoo! Finance
